economy
January 21, 2026
Johnson & Johnson forecasts 2026 profit above Wall Street estimates
Johnson & Johnson also reported a fourth-quarter profit ahead of expectations, buoyed by strong sales of the blood cancer therapy Darzalex.
TL;DR
- J&J forecasts 2026 sales between $99.5 billion and $100.5 billion, surpassing analyst estimates.
- The company anticipates 2026 earnings per share of $11.43 to $11.63.
- A drug pricing deal with the Trump administration will impact J&J by hundreds of millions of dollars.
- Fourth-quarter profit and revenue exceeded analyst expectations.
- Strong sales of Darzalex and Tremfya, along with resilience in medical devices, boosted Q4 results.
- Stelara sales declined more than anticipated, but other product portfolios showed significant growth.
- J&J is facing challenges including tariff uncertainty and biosimilar competition for Stelara.
- A special master recommended allowing expert testimony linking J&J's talc products to ovarian cancer.
Continue reading the original article